<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>4900</id>
    <completedYear/>
    <publishedYear>2024</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>16</pageNumber>
    <edition/>
    <issue>6</issue>
    <volume>19</volume>
    <articleNumber>e0304324</articleNumber>
    <type>article</type>
    <publisherName>PLOS</publisherName>
    <publisherPlace>San Francisco</publisherPlace>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>2024-07-15</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer—Results of the prospective multicenter PERMAD trial</title>
    <abstract language="eng">Background&#13;
Anti-vascular endothelial growth factor (VEGF) monoclonal antibodies (mAbs) are widely used for tumor treatment, including metastatic colorectal cancer (mCRC). So far, there are no biomarkers that reliably predict resistance to anti-VEGF mAbs like bevacizumab. A biomarker-guided strategy for early and accurate assessment of resistance could avoid the use of non-effective treatment and improve patient outcomes. We hypothesized that repeated analysis of multiple cytokines and angiogenic growth factors (CAFs) before and during treatment using machine learning could provide an accurate and earlier, i.e., 100 days before conventional radiologic staging, prediction of resistance to first-line mCRC treatment with FOLFOX plus bevacizumab.&#13;
&#13;
Patients and methods&#13;
15 German and Austrian centers prospectively recruited 50 mCRC patients receiving FOLFOX plus bevacizumab as first-line treatment. Plasma samples were collected every two weeks until radiologic progression (RECIST 1.1) as determined by CT scans performed every 2 months. 102 pre-selected CAFs were centrally analyzed using a cytokine multiplex assay (Luminex, Myriad RBM).&#13;
&#13;
Results&#13;
Using random forests, we developed a predictive machine learning model that discriminated between the situations of “no progress within 100 days before radiological progress” and “progress within 100 days before radiological progress”. We could further identify a combination of ten out of the 102 CAF markers, which fulfilled this task with 78.2% accuracy, 71.8% sensitivity, and 82.5% specificity.&#13;
&#13;
Conclusions&#13;
We identified a CAF marker combination that indicates treatment resistance to FOLFOX plus bevacizumab in patients with mCRC within 100 days prior to radiologic progress.</abstract>
    <parentTitle language="eng">PLOS ONE</parentTitle>
    <identifier type="issn">1932-6203</identifier>
    <identifier type="urn">urn:nbn:de:bvb:573-49003</identifier>
    <enrichment key="opus_doi_flag">true</enrichment>
    <enrichment key="opus_import_data">{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:27:29Z","timestamp":1718411249162},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"&lt;jats:sec id=\"sec001\"&gt;\n&lt;jats:title&gt;Background&lt;\/jats:title&gt;\n&lt;jats:p&gt;Anti-vascular endothelial growth factor (VEGF) monoclonal antibodies (mAbs) are widely used for tumor treatment, including metastatic colorectal cancer (mCRC). So far, there are no biomarkers that reliably predict resistance to anti-VEGF mAbs like bevacizumab. A biomarker-guided strategy for early and accurate assessment of resistance could avoid the use of non-effective treatment and improve patient outcomes. We hypothesized that repeated analysis of multiple cytokines and angiogenic growth factors (CAFs) before and during treatment using machine learning could provide an accurate and earlier, i.e., 100 days before conventional radiologic staging, prediction of resistance to first-line mCRC treatment with FOLFOX plus bevacizumab.&lt;\/jats:p&gt;\n&lt;\/jats:sec&gt;\n&lt;jats:sec id=\"sec002\"&gt;\n&lt;jats:title&gt;Patients and methods&lt;\/jats:title&gt;\n&lt;jats:p&gt;15 German and Austrian centers prospectively recruited 50 mCRC patients receiving FOLFOX plus bevacizumab as first-line treatment. Plasma samples were collected every two weeks until radiologic progression (RECIST 1.1) as determined by CT scans performed every 2 months. 102 pre-selected CAFs were centrally analyzed using a cytokine multiplex assay (Luminex, Myriad RBM).&lt;\/jats:p&gt;\n&lt;\/jats:sec&gt;\n&lt;jats:sec id=\"sec003\"&gt;\n&lt;jats:title&gt;Results&lt;\/jats:title&gt;\n&lt;jats:p&gt;Using random forests, we developed a predictive machine learning model that discriminated between the situations of \u201cno progress within 100 days before radiological progress\u201d and \u201cprogress within 100 days before radiological progress\u201d. We could further identify a combination of ten out of the 102 CAF markers, which fulfilled this task with 78.2% accuracy, 71.8% sensitivity, and 82.5% specificity.&lt;\/jats:p&gt;\n&lt;\/jats:sec&gt;\n&lt;jats:sec id=\"sec004\"&gt;\n&lt;jats:title&gt;Conclusions&lt;\/jats:title&gt;\n&lt;jats:p&gt;We identified a CAF marker combination that indicates treatment resistance to FOLFOX plus bevacizumab in patients with mCRC within 100 days prior to radiologic progress.&lt;\/jats:p&gt;\n&lt;\/jats:sec&gt;","DOI":"10.1371\/journal.pone.0304324","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T17:24:02Z","timestamp":1718385842000},"page":"e0304324","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer\u2014Results of the prospective multicenter PERMAD trial"],"prefix":"10.1371","volume":"19","author":[{"given":"Thomas","family":"Seufferlein","sequence":"first","affiliation":[]},{"given":"Ludwig","family":"Lausser","sequence":"additional","affiliation":[]},{"given":"Alexander","family":"Stein","sequence":"additional","affiliation":[]},{"given":"Dirk","family":"Arnold","sequence":"additional","affiliation":[]},{"given":"Gerald","family":"Prager","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-5947-8733","authenticated-orcid":true,"given":"Stefan","family":"Kasper-Virchow","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Niedermeier","sequence":"additional","affiliation":[]},{"given":"Lothar","family":"M\u00fcller","sequence":"additional","affiliation":[]},{"given":"Stefan","family":"Kubicka","sequence":"additional","affiliation":[]},{"given":"Alexander","family":"K\u00f6nig","sequence":"additional","affiliation":[]},{"given":"Petra","family":"B\u00fcchner-Steudel","sequence":"additional","affiliation":[]},{"given":"Kai","family":"Wille","sequence":"additional","affiliation":[]},{"given":"Andreas W.","family":"Berger","sequence":"additional","affiliation":[]},{"given":"Angelika M. R.","family":"Kestler","sequence":"additional","affiliation":[]},{"given":"Johann M.","family":"Kraus","sequence":"additional","affiliation":[]},{"given":"Silke D.","family":"Werle","sequence":"additional","affiliation":[]},{"given":"Lukas","family":"Perkhofer","sequence":"additional","affiliation":[]},{"given":"Thomas J.","family":"Ettrich","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-4759-5254","authenticated-orcid":true,"given":"Hans A.","family":"Kestler","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"issue":"5","key":"pone.0304324.ref001","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"D Hanahan","year":"2011","journal-title":"Cell"},{"key":"pone.0304324.ref002","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2018.10.009","article-title":"Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis","volume":"106","author":"A Baraniskin","year":"2019","journal-title":"European Journal of Cancer"},{"issue":"23","key":"pone.0304324.ref003","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer","volume":"350","author":"H Hurwitz","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"pone.0304324.ref004","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/annonc\/mdu260","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"E Van Cutsem","year":"2014","journal-title":"Annals of Oncology"},{"key":"pone.0304324.ref005","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JGO.19.00367","article-title":"Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline","volume":"6","author":"EG Chiorean","year":"2020","journal-title":"JCO Global Oncology"},{"issue":"12","key":"pone.0304324.ref006","first-page":"1344","article-title":"S3-Leitlinie \u2013Kolorektales Karzinom","volume":"55","author":"W Schmiegel","year":"2017","journal-title":"Z Gastroenterol"},{"issue":"1","key":"pone.0304324.ref007","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial","volume":"14","author":"J Bennouna","year":"2013","journal-title":"The Lancet Oncology"},{"key":"pone.0304324.ref008","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fonc.2020.00221","article-title":"Resistance Mechanisms to Anti-angiogenic Therapies in Cancer","volume":"10","author":"Y Haibe","year":"2020","journal-title":"Front Oncol"},{"issue":"3","key":"pone.0304324.ref009","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2009.24.8252","article-title":"Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance","volume":"28","author":"S Kopetz","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"pone.0304324.ref010","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"G Bergers","year":"2008","journal-title":"Nature Reviews Cancer"},{"issue":"4","key":"pone.0304324.ref011","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.it.2015.02.005","article-title":"Intertwined regulation of angiogenesis and immunity by myeloid cells","volume":"36","author":"LB Rivera","year":"2015","journal-title":"Trends in Immunology"},{"issue":"3","key":"pone.0304324.ref012","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1158\/1078-0432.CCR-19-1985","article-title":"Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Post Hoc Analysis of the VELOUR Trial","volume":"26","author":"E Van Cutsem","year":"2020","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"pone.0304324.ref013","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1038\/s41467-018-07174-1","article-title":"Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer","volume":"9","author":"GC Jayson","year":"2018","journal-title":"Nature Communications"},{"issue":"25","key":"pone.0304324.ref014","doi-asserted-by":"crossref","first-page":"14863","DOI":"10.1073\/pnas.95.25.14863","article-title":"Cluster analysis and display of genome-wide expression patterns","volume":"95","author":"MB Eisen","year":"1998","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"pone.0304324.ref015","doi-asserted-by":"crossref","volume-title":"Cluster analysis","author":"BS Everitt","year":"2011","DOI":"10.1002\/9780470977811"},{"key":"pone.0304324.ref016","doi-asserted-by":"crossref","volume-title":"Evaluating Learning Algorithms: A Classification Perspective","author":"N Japkowicz","year":"2011","DOI":"10.1017\/CBO9780511921803"},{"issue":"1","key":"pone.0304324.ref017","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random forests","volume":"45","author":"L Breiman","year":"2001","journal-title":"Machine Learning"},{"issue":"3","key":"pone.0304324.ref018","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/BF00994018","article-title":"Support-vector networks","volume":"20","author":"C Cortes","year":"1995","journal-title":"Machine Learning"},{"key":"pone.0304324.ref019","doi-asserted-by":"crossref","unstructured":"Fix E, Hodges JL. Discriminatory Analysis: Nonparametric Discrimination: Consistency Properties. USAF School of Aviation Medicine, Randolf Field, Texas; 1951. Project 21-49-004, Report Number 4.","DOI":"10.1037\/e471672008-001"},{"issue":"5","key":"pone.0304324.ref020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v046.i05","article-title":"Multi-Objective Parameter Selection for Classifiers","volume":"46","author":"C M\u00fcssel","year":"2012","journal-title":"Journal of Statistical Software"},{"issue":"19","key":"pone.0304324.ref021","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/jnci\/djh275","article-title":"Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging","volume":"96","author":"JB O\u2019Connell","year":"2004","journal-title":"JNCI: Journal of the National Cancer Institute"},{"issue":"4","key":"pone.0304324.ref022","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","article-title":"Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"21","author":"C Cremolini","year":"2020","journal-title":"The Lancet Oncology"},{"issue":"13","key":"pone.0304324.ref023","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(15)00042-X","article-title":"Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial","volume":"16","author":"S Hegewisch-Becker","year":"2015","journal-title":"The Lancet Oncology"},{"issue":"1","key":"pone.0304324.ref024","doi-asserted-by":"crossref","first-page":"1832761","DOI":"10.1080\/2162402X.2020.1832761","article-title":"Expression of the immune modulator secretory leukocyte protease inhibitor (SLPI) in colorectal cancer liver metastases and matched primary tumors is associated with a poorer prognosis","volume":"9","author":"S Nugteren","year":"2020","journal-title":"OncoImmunology"},{"issue":"16","key":"pone.0304324.ref025","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1158\/0008-5472.CAN-18-3657","article-title":"Activation of the VEGFC\/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer","volume":"79","author":"C Tacconi","year":"2019","journal-title":"Cancer Research"},{"issue":"1","key":"pone.0304324.ref026","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/172460080001500108","article-title":"Tissue-Type Plasminogen Activator (tPA) Content in Colorectal Cancer and in Surrounding Mucosa: Relationship with Clinicopathologic Parameters and Prognostic Significance","volume":"15","author":"P Raigoso","year":"2000","journal-title":"The International Journal of Biological Markers"},{"issue":"13","key":"pone.0304324.ref027","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.3390\/cancers14133106","article-title":"Implication of Hepsin from primary tumor in the prognosis of colorectal cancer patients","volume":"14","author":"D Zaragoza-Huesca","year":"2022","journal-title":"Cancers"},{"issue":"11","key":"pone.0304324.ref028","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1111\/cas.14198","article-title":"Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer","volume":"110","author":"T Hamaguchi","year":"2019","journal-title":"Cancer Science"},{"issue":"9","key":"pone.0304324.ref029","doi-asserted-by":"crossref","first-page":"e1330","DOI":"10.1002\/cti2.1330","article-title":"IgM and IgA augmented autoantibody signatures improve early-stage detection of colorectal cancer prior to nodal and distant spread","volume":"10","author":"MSI Roney","year":"2021","journal-title":"Clinical &amp; Translational Immunology"},{"issue":"3","key":"pone.0304324.ref030","first-page":"813","article-title":"IGFBP-1 in cancer: expression, molecular mechanisms, and potential clinical implications","volume":"13","author":"YW Lin","year":"2021","journal-title":"Am J Transl Res"},{"key":"pone.0304324.ref031","doi-asserted-by":"crossref","first-page":"940706","DOI":"10.3389\/fonc.2022.940706","article-title":"Increased MPO in Colorectal Cancer Is Associated With High Peripheral Neutrophil Counts and a Poor Prognosis: A TCGA With Propensity Score-Match Analysis","volume":"12","author":"M Weng","year":"2022","journal-title":"Frontiers in Oncology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0304324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T17:24:28Z","timestamp":1718385868000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0304324"}},"subtitle":[],"editor":[{"given":"James","family":"Mockridge","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,14]]}},"URL":"http:\/\/dx.doi.org\/10.1371\/journal.pone.0304324","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]}}}</enrichment>
    <enrichment key="local_crossrefDocumentType">journal-article</enrichment>
    <enrichment key="local_crossrefLicence">http://creativecommons.org/licenses/by/4.0/</enrichment>
    <enrichment key="local_import_origin">crossref</enrichment>
    <enrichment key="local_doiImportPopulated">PersonEditorFirstName_1,PersonEditorLastName_1,PersonAuthorFirstName_1,PersonAuthorLastName_1,PersonAuthorFirstName_2,PersonAuthorLastName_2,PersonAuthorFirstName_3,PersonAuthorLastName_3,PersonAuthorFirstName_4,PersonAuthorLastName_4,PersonAuthorFirstName_5,PersonAuthorLastName_5,PersonAuthorFirstName_6,PersonAuthorLastName_6,PersonAuthorIdentifierOrcid_6,PersonAuthorFirstName_7,PersonAuthorLastName_7,PersonAuthorFirstName_8,PersonAuthorLastName_8,PersonAuthorFirstName_9,PersonAuthorLastName_9,PersonAuthorFirstName_10,PersonAuthorLastName_10,PersonAuthorFirstName_11,PersonAuthorLastName_11,PersonAuthorFirstName_12,PersonAuthorLastName_12,PersonAuthorFirstName_13,PersonAuthorLastName_13,PersonAuthorFirstName_14,PersonAuthorLastName_14,PersonAuthorFirstName_15,PersonAuthorLastName_15,PersonAuthorFirstName_16,PersonAuthorLastName_16,PersonAuthorFirstName_17,PersonAuthorLastName_17,PersonAuthorFirstName_18,PersonAuthorLastName_18,PersonAuthorFirstName_19,PersonAuthorLastName_19,PersonAuthorIdentifierOrcid_19,PublisherName,TitleMain_1,Language,TitleAbstract_1,TitleParent_1,Issue,Volume,CompletedYear,IdentifierIssn,Enrichmentlocal_crossrefLicence</enrichment>
    <enrichment key="opus.source">doi-import</enrichment>
    <enrichment key="THI_relatedIdentifier">https://doi.org/10.1371/journal.pone.0304324</enrichment>
    <enrichment key="THI_articleversion">published</enrichment>
    <enrichment key="THI_openaccess">ja</enrichment>
    <enrichment key="THI_review">peer-review</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>Creative Commons BY 4.0</licence>
    <author>
      <first_name>Thomas</first_name>
      <last_name>Seufferlein</last_name>
    </author>
    <author>
      <first_name>Ludwig</first_name>
      <last_name>Lausser</last_name>
    </author>
    <author>
      <first_name>Alexander</first_name>
      <last_name>Stein</last_name>
    </author>
    <author>
      <first_name>Dirk</first_name>
      <last_name>Arnold</last_name>
    </author>
    <author>
      <first_name>Gerald</first_name>
      <last_name>Prager</last_name>
    </author>
    <author>
      <first_name>Stefan</first_name>
      <last_name>Kasper-Virchow</last_name>
    </author>
    <author>
      <first_name>Michael</first_name>
      <last_name>Niedermeier</last_name>
    </author>
    <author>
      <first_name>Lothar</first_name>
      <last_name>Müller</last_name>
    </author>
    <author>
      <first_name>Stefan</first_name>
      <last_name>Kubicka</last_name>
    </author>
    <author>
      <first_name>Alexander</first_name>
      <last_name>König</last_name>
    </author>
    <author>
      <first_name>Petra</first_name>
      <last_name>Büchner-Steudel</last_name>
    </author>
    <author>
      <first_name>Kai</first_name>
      <last_name>Wille</last_name>
    </author>
    <author>
      <first_name>Andreas W.</first_name>
      <last_name>Berger</last_name>
    </author>
    <author>
      <first_name>Angelika M. R.</first_name>
      <last_name>Kestler</last_name>
    </author>
    <author>
      <first_name>Johann M.</first_name>
      <last_name>Kraus</last_name>
    </author>
    <author>
      <first_name>Silke D.</first_name>
      <last_name>Werle</last_name>
    </author>
    <author>
      <first_name>Lukas</first_name>
      <last_name>Perkhofer</last_name>
    </author>
    <author>
      <first_name>Thomas J.</first_name>
      <last_name>Ettrich</last_name>
    </author>
    <author>
      <first_name>Hans A.</first_name>
      <last_name>Kestler</last_name>
    </author>
    <collection role="open_access" number="">open_access</collection>
    <collection role="institutes" number="19309">Fakultät Informatik</collection>
    <collection role="persons" number="49455">Lausser, Ludwig</collection>
    <thesisPublisher>Technische Hochschule Ingolstadt</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-haw/files/4900/journal.pone.0304324.pdf</file>
  </doc>
</export-example>
